دورية أكاديمية
Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors
| العنوان: | Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors |
|---|---|
| المؤلفون: | Ludovico Abenavoli, Michele Montori, Gianluca Svegliati Baroni, Maria Eva Argenziano, Francesca Giorgi, Giuseppe Guido Maria Scarlata, Francesca Ponziani, Emidio Scarpellini |
| المصدر: | Medicina, Vol 59, Iss 8, p 1427 (2023) |
| بيانات النشر: | MDPI AG, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Medicine (General) |
| مصطلحات موضوعية: | immunotherapy, checkpoint inhibitors, gut microbiota, fecal microbiota transplantation, Medicine (General), R5-920 |
| الوصف: | Background and Objectives: Hepatocellular carcinoma (HCC) is the leading cause of liver cancer worldwide and has a high mortality rate. Its incidence has increased due to metabolic-associated liver disease (MAFLD) epidemics. Liver transplantation and surgery remain the most resolute measures. Despite the optimistic use of multi-kinase inhibitors, namely sorafenib, the co-existence of chronic liver disease made the response rate low in these patients. Immune checkpoint inhibitors (ICIs) have become a promising hope for certain advanced solid tumors and, also, for advanced HCC. Unfortunately, a large cohort of patients with HCC fail to respond to immunotherapy. Materials and Methods: We conducted a narrative search on the main medical databases for original articles, reviews, meta-analyses, randomized clinical trials, and case series using the following keywords and acronyms and their associations: hepatocellular carcinoma, immunotherapy, checkpoint inhibitors, gut microbiota, and fecal microbiota transplantation. Results: ICIs are a promising and sufficiently safe treatment option for HCC. In detail, they have significantly improved survival and prognosis in these patients vs. sorafenib. Although there are several highlighted mechanisms of resistance, the gut microbiota signature can be used both as a response biomarker and as an effect enhancer. Practically, probiotic dose-finding and fecal microbiota transplantation are the weapons that can be used to increase ICI’s treatment-response-reducing resistance mechanisms. Conclusion: Immunotherapy has been a significant step-up in HCC treatment, and gut microbiota modulation is an effective liaison to increase its efficacy. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1648-9144 1010-660X |
| Relation: | https://www.mdpi.com/1648-9144/59/8/1427; https://doaj.org/toc/1010-660X; https://doaj.org/toc/1648-9144 |
| DOI: | 10.3390/medicina59081427 |
| URL الوصول: | https://doaj.org/article/98f2f29b72974134ae22a882370fc11b |
| رقم الأكسشن: | edsdoj.98f2f29b72974134ae22a882370fc11b |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 16489144 1010660X |
|---|---|
| DOI: | 10.3390/medicina59081427 |